BTA biota holdings limited

media coverage, page-4

  1. 1,373 Posts.
    You can't seriously imagine GSK could BTA by paying $2.35/share do you? Who would agree to that? A takeover premium would price it closer to $12 with all the associated hype around vastly increased demand for Relenza, LANI and other BTA blue sky projects. I also doubt Costello would wear it given adverse publicity surounding the court case and Sankyo would be highly resistant as a JV partner.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.